A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Status: Recruiting
Phase: Phase 2
DFCI Protocol ID: 11-084

The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after imatinib or who are resistant or intolerant to imatinib. The side effects of this oral investigational drug in children and adolescents will be evaluated

Conducting Institutions:

Dana-Farber Cancer Institute, Children's Hospital Boston

Overall PI:

Barbara Degar, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP, ctip@partners.org

Eligibility Criteria

Inclusion Criteria:

  -  CP-CML who prove resistant or intolerant to imatinib (cohort #1)

  -  Ph+ ALL, AP-CML, or BP-CML who are resistant or intolerant to or who relapse after

     imatinib therapy (cohort #2)

  -  Newly diagnosed, treatment naive CP-CML (cohort #3)

  -  Lansky or Karnofsky scale > 50

  -  Life expectancy Ì¢‰Û¡å´ 12 weeks

  -  Adequate hepatic and renal function

  -  Written informed consent

Exclusion Criteria:

  -  Eligibility for potentially-curative therapy including hematopoietic stem-cell


  -  Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal


  -  Isolated extramedullary disease

  -  Prior therapy with dasatinib

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.